But they locked 50% at $3.62. God knows what the other half hedging price is. We will figure out by 5/1.
And unfortunately, you might be right again today and for the next several weeks.
Good bless.
OK I was wrong. that was for NG equ, not NG. For NG, Q3 $2.07, Q4 $1.97, Full year $2.07
That is in the last Quarterly report. Q3 $4.04, Q4 $4.23, Full year $4.02. Take a look at it yourself.
CHK did not hedge NG price in 2012 and with price of NG as low as $1.92, the realize gain from NG for the full year 2012 is average of $4.02. How did that happen?
Now with 50% hedged at $3.62, even if CHK sells the rest at $4.25, the rev from NG will still be lower than that of 2012, is that correct? Or did I miss anything?
It will be very hard to dose higher. At 0.6 mg/kg, you are dosing about 42 mg per person. optimal at 30 mg/mL, that is about 1.5 mL for subQ. Not likely to go higher. Not working.
Sentiment: Strong Sell
First of all, that is not the primary end point, which it failed. Secondly, I would not call 0.077 statistically significant.
Sentiment: Strong Sell
Inflammatory lesion counts is the primary endpoint in this trial. The magnitude of the difference was substantially maintained throughout the study, but differences at later measurement points were not statistically significant. Failed.
Sentiment: Strong Sell
You will be luck if not dropping like poop.
Sentiment: Sell
Not a surprise. Expect another small drop to $2.5 pps level.
Sentiment: Sell
Very thoughtful interpretation.
Sentiment: Strong Buy
It seems that his arms were twisted when his Sr executives were fired. What I am afraid from his presentation today was that he won't be there long either by jumping or being pushed.
Sentiment: Sell
CEO is lethagic. Does not seems to be confident and excited. I am out.
Sentiment: Strong Sell